Abstract:Background: Downregulation of MHC class I expression and/or defects in the antigen presentation pathways are commonly reported in human cancers. Numerous studies previously have explored extensively the molecular mechanisms that underlie HLA-class I and Beta2-Microglobulin (B2M) downregulation. However, the techniques presently available to detect expression of MHC class I proteins lack the robustness, specificity and sensitivity needed for systematic integration and analysis in clinical trials. Furthermore, the dynamics of HLA-class I and B2M expression have not been comprehensively studied as a potential biomarker for immunotherapy. Methods: Using novel, validated, immunohistochemistry (IHC)-based methods for quantifying B2M and HLA-A in tumor samples from diverse cancer types, we have determined loss of B2M and HLA-A proteins in 336 archived, primary specimens and 329 biopsies from metastatic patients collected during Roche-sponsored Phase 1 clinical trials investigating novel immunotherapy candidates as monotherapy or in combination with CPI. Results: Up to 56% of cases with B2M or HLA-A loss were noted in the investigated tumor types. The frequency of loss was dependent on indication and stage of disease and revealed heterogeneous expression patterns across patients. B2M and HLA-A loss was increased in metastatic lesions compared to primary tumors, indicating selection of MHC class I low clones in metastatic and refractory tumor cells. High on-treatment B2M expression correlated with successful clinical outcome (RECIST), while high baseline B2M did not. A treatment-induced increase of B2M expression was noted in most of the patients with low B2M levels at baseline. The triple biomarker combination of B2M, CD8 and PDL1 strongly improved response prediction to cancer immunotherapy. Conclusion: Our results indicate that B2M and HLA-A loss occurs frequently in tumors and is reversed in most instances following immunotherapy which supports the conclusion that MHC class I loss is not the dominant resistance mechanism to CPI treatment. This investigation reveals a highly dynamic expression of HLA-A and B2M in tumors affected by indication, metastatic status, immunophenotype and immunotherapy treatment. Baseline expression levels of B2M on tumors may be of utility as a constituent of a biomarker panel used for selecting patients for immunotherapy clinical trials.

Beta2-Microglobulin(B2m) In Cancer Immunotherapies: Biological Function, Resistance And Remedy

β2-microglobulin expression is associated with aggressive histology, activated tumor immune milieu, and outcome in colon carcinoma

Effect of Exonic Microsatellite Instability of B2M on the Predictability of MSI/dMMR for Immunotherapy.

Tumor beta2-microglobulin and HLA-A expression is increased by immunotherapy and can predict response to CIT in association with other biomarkers

Beta-2-microglobulin Mutations Are Linked to a Distinct Metastatic Pattern and a Favorable Outcome in Microsatellite-Unstable Stage IV Gastrointestinal Cancers

Prevalence and Associations of Beta2-Microglobulin Mutations in MSI-H/dMMR Cancers

Immune checkpoint blockade resistance-related B2M hotspot mutations in microsatellite-unstable colorectal carcinoma

2-Microglobulin Maintains Glioblastoma Stem Cells and Induces M2-like Polarization of Tumor-Associated Macrophages

Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy

Immune Cells Within the Tumor Microenvironment: Biological Functions and Roles in Cancer Immunotherapy

Neglected no more: B cell-mediated anti-tumor immunity

Human Epithelial-Type Ovarian Tumour Marker Beta-2-microglobulin is Regulated by the TGF-β Signaling Pathway

Chapter 2 Biological Response Modifier in Cancer Immunotherapy

B7-H3 in tumors: friend or foe for tumor immunity?

Immune status for monitoring and treatment of bladder cancer

Application of Bionanomaterials in Tumor Immune Microenvironment Therapy

Multiple myeloma and the potential of new checkpoint inhibitors for immunotherapy

β2-microglobulin maintains glioblastoma stem cells and induces M2-like polarization of tumor-associated macrophages

Roles and mechanisms of tumour-infiltrating B cells in human cancer: a new force in immunotherapy

Immune cells in the B-cell lymphoma microenvironment: From basic research to clinical applications

Bionic Immunoactivator Copresenting Autophagy Promoting and Costimulatory Molecules for Synergistic Cancer Immunotherapy